logo
Share SHARE
FONT-SIZE Plus   Neg

Pre-market Movers For Feb 23 (VVUS, TGT, SHLD, ARNA, HPQ, CKP, CHTP)

Gainers:

Target Corp. (TGT) is up 0.06 percent at $53.00. The company's fourth quarter profit declined from the year-ago quarter. However, adjusted earnings per share were above Wall Street view. Total revenues improved 3 percent and were slightly above consensus. The company's first quarter and 2012 earnings per share guidance was above estimates.

VIVUS, Inc. (VVUS) is jumping 103 percent to $21.45 based on the news that a FDA panel has recommended approval of its lead obesity drug Qnexa. The Endocrinologic and Metabolic Drugs Advisory Committee has voted 20 to 2 while recommending that Qnexa be granted marketing approval to treat obesity in adults.

Sears Holdings Corp. (SHLD) is up 2 percent to $53.10. The company announced its intention to separate its Sears Hometown and Outlet Businesses and certain hardware stores through a proposed rights offering that is expected to raise approximately $400 million to $500 million. Meanwhile, the company slipped to a loss in its fourth quarter and also reported a 3.4 percent domestic comparable store sales decline.

Arena Pharmaceuticals, Inc. (ARNA) is up 19 percent at $2.16.

Decliners:

Hewlett-Packard Co. (HPQ) is down 3 percent to $28.10. The company's first quarter earnings declined 44 percent from the year-ago quarter. The company's earnings per share, excluding items, were above analysts' expectations, but revenue was below consensus.

Checkpoint Systems, Inc. (CKP) down over 3 percent to $11.50. The company slipped to a loss in its fourth quarter and its adjusted loss per share was larger than what analysts' had estimated. The company said the ongoing global economic uncertainty and unpredictable retailer behavior impacted its 2011 results and remain a concern near-term.

Trading halt:

Trading in shares of Chelsea Therapeutics International (CHTP) was halted, pending news.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The month of February saw the FDA approve the second drug for Duchenne muscular dystrophy namely Emflaza. Now, let's take a look at the biotech stocks awaiting FDA decision in March. The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier.
comments powered by Disqus
Follow RTT